Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
NCT07041788Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in head and neck squamous cell carcinoma (HNSCC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Event-Free Survival at 2 years. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07041788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041788.